secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2025-12-05T23:59:59+00:00
Accession:  0001104659-25-118664
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera acquires Foresight Diagnostics for $275M upfront plus $175M earnouts
---------------------------------------------------------------------------

- All-stock acquisition includes $275M upfront consideration plus up to $175M in revenue- and reimbursement-based milestone earnouts.
- Adds Foresight's PhasED-Seq phased variant technology with LOD95 of 0.3 ppm, enhancing Signatera MRD platform.
- Expands Natera's presence in lymphoma, with Foresight's CLARITY MRD assay used in three prospective trials and NCCN guideline inclusion.
- Integration of phased variants into Signatera platform expected to be launched for clinical use in 2026.
- Company issued 1,127,982 shares upfront and up to ~824,583 additional contingent shares; will file registration for resale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465925118664/0001104659-25-118664-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465925118664/tm2532406d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-118664

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer